Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in anti-inflammatory therapy.

D Aletaha1, J S Smolen

  • 1Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna. Daniel.Aletaha@akh-wien.ac.at

Acta Medica Austriaca
|March 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.

Scandinavian journal of rheumatology·2020
Same author

Preface.

Seminars in arthritis and rheumatism·2019
Same author

Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis.

Scandinavian journal of rheumatology·2019
Same author

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2018
Same author

Advances in targeted therapies 2017.

Clinical immunology (Orlando, Fla.)·2018
Same author

Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.

Arthritis research & therapy·2017

Nonsteroidal anti-inflammatory drugs (NSAIDs) commonly treat rheumatoid arthritis (RA), but can cause gastrointestinal issues. Protective therapies did not reduce adverse events in this study.

Area of Science:

  • Rheumatology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) management before coxibs relied heavily on nonsteroidal anti-inflammatory drugs (NSAIDs).
  • NSAIDs were frequently used alongside disease-modifying antirheumatic drugs (DMARDs) in RA patients.
  • Gastrointestinal (GI) toxicity is a known concern with NSAID use.

Purpose of the Study:

  • To evaluate NSAID use and associated GI toxicity in rheumatoid arthritis patients before the coxib era.
  • To assess the effectiveness of GI-protective therapies in mitigating NSAID-related adverse events.

Main Methods:

  • Retrospective analysis of 368 RA patients treated between 1972-1998.
  • Data collected on NSAID and DMARD therapy, including duration and specific agents used.
  • Evaluation of concurrent GI-protective strategies (histamine antagonists, sucralfate) and incidence of GI adverse events.

Related Experiment Videos

Main Results:

  • Diclofenac was the most common NSAID, used in 60% of therapies.
  • Seventy-two percent of patients received GI-protective therapy.
  • GI-related adverse events, primarily dyspepsia and nausea, occurred similarly in patients with and without GI protection.

Conclusions:

  • NSAIDs pose a significant risk of GI adverse events in RA patients.
  • Histamine antagonists and sucralfate were ineffective in reducing the incidence of NSAID-induced GI adverse events in this cohort.